Novartis stock trades steady as Cosentyx growth supports outlook

Novartis AG (ISIN CH0012005267) stock is anchored by rising revenue and profit from its core innovative medicines business, with recent quarterly figures showing growth backed by flagship therapies such as Cosentyx and Entresto as of 18 April 2024 according to the company’s latest reported financial results.

Revenue up in recent quarter

According to Novartis’ investor relations information, the group reported higher net sales in its most recently available quarter, with total revenue for that period in early 2024 reaching several billion dollars and continuing the trend of year on year growth.

The company highlighted that growth was driven by its innovative medicines division, which includes key products for immunology, cardiology, and oncology, and management emphasized that this segment remains central to the long term strategy of Novartis.

Novartis also pointed to operating profit expansion during the same quarter, noting that core operating income increased compared with the year earlier period, benefitting from a richer mix of high value therapies and ongoing productivity efforts across its portfolio.

Profitability supported by Cosentyx and Entresto

In its recent financial updates, Novartis has underscored the contribution of immunology drug Cosentyx and heart failure treatment Entresto to both top line and earnings, with the company explaining that these medicines generated strong sales growth compared with prior quarters and prior year levels.

Cosentyx, which is indicated for conditions such as psoriasis and psoriatic arthritis, delivered higher revenue in the latest reported quarter as physicians continued to adopt the therapy in key markets, a trend management described on the company’s earnings materials as an important driver of segment performance.

Entresto, used in chronic heart failure, also showed an increase in sales versus the same period a year earlier, reflecting broader guideline support and market penetration in major geographies, and Novartis indicated that this medicine is a meaningful contributor to recurring revenue.

Cosentyx drives immunology revenue

Cosentyx has become one of Novartis’ largest products in immunology, and the company’s disclosures show that in recent reporting periods its sales increased compared with the previous year, supported by new indications and sustained demand among dermatology and rheumatology prescribers.

Novartis noted that Cosentyx’s growth in key markets contributed to higher total immunology revenue and that further label expansions and geographic launches are intended to maintain this momentum, according to information available on the Novartis investors pages.

Novartis stock and recent trading context

Novartis stock is listed on SIX Swiss Exchange and has an additional listing on the New York Stock Exchange through American Depositary Receipts, giving it exposure to both European and US investor bases, as shown by the trading venue information presented in investor materials.

Market data pages cited by Novartis indicate that the company’s equity valuation amounts to tens of billions of Swiss francs in market capitalization as of early 2024, placing Novartis among the largest healthcare constituents of key indices such as the SMI.

For investors, the interplay between revenue growth, profitability improvement and the sustainability of demand for leading therapies like Cosentyx and Entresto continues to shape sentiment around Novartis stock in the medium term.

Core immunology and oncology products

Novartis sells a wide range of innovative medicines, and recent financial communications highlight that immunology, oncology and cardiology are pillars of the portfolio, with multiple blockbuster or near blockbuster products contributing to revenue.

The company has also emphasized its pipeline of new molecules, including advanced therapies that it expects will support long term growth in areas such as gene therapy and targeted cancer treatments, according to material accessible via the Novartis pipeline overview.

Novartis stock closing context

In recent months, Novartis stock has traded in a range consistent with its large cap healthcare peers listed on SIX Swiss Exchange, reflecting both company specific factors and broader sector sentiment.